ZGNX Zogenix, Inc.

10.40
+0  (0%)
Previous Close 10.35
Open 10.35
Price To book 2.13
Market Cap 258.06M
Shares 24,813,000
Volume 124,881
Short Ratio 10.32
Av. Daily Volume 306,910

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2017.
ZX008
Lennox-Gastaut syndrome
Approved July 16, 2009.
Sumavel
Migraine
Phase 3 initiation of efficacy portion announced February 13, 2017.
ZX008 - Study 1504
Dravet syndrom
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Approved October 25, 2013.
Zohydro ER
Moderate to severe pain
Phase 3 data due 3Q 2017.
ZX008 - (Study 1)
Dravet syndrom
Approved January 30, 2015.
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain

Latest News

  1. Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  2. Zogenix, Inc. :ZGNX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  3. ZOGENIX, INC. Financials
  4. Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference
  5. ZOGENIX, INC. Files SEC form 10-K, Annual Report
  6. Zogenix reports 4Q loss
  7. Zogenix reports 4Q loss
  8. ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  9. Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
  10. Q4 2016 Zogenix Inc Earnings Release - After Market Close
  11. Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9
  12. Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
  13. ZOGENIX, INC. Files SEC form 8-K, Other Events
  14. Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference
  15. Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome
  16. Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
  17. ZOGENIX, INC. Files SEC form 8-K, Other Events
  18. Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome
  19. Blog Coverage Novartis Announced Buyback of Shares Worth $5 Billion; Considers Strategic Options for Alcon Division
  20. ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial